Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Licensing Agreement to Develop Stem Cell Based Breast Cancer Diagnostic

Published: Tuesday, July 01, 2014
Last Updated: Tuesday, July 01, 2014
Bookmark and Share
Building an oncology franchise.

Tiziana Life Sciences has announced that it has entered into an exclusive license agreement with TTFactor S.r.l. ("the Licensor", acting on behalf of the FIRC (the Italian Foundation for Cancer Research) Institute for Molecular Oncology (IFOM), and the European Institute of Oncology (IEO)), covering the use of twenty defined stem cell markers (the "TOP 20") for patient stratification in breast cancer.

The TOP 20 model is a gene expression signature capable of predicting disease aggressiveness and prognosis in breast cancer patients. It is different from all other signatures available today because it is derived from cancer stem cells and therefore it predicts cancer behaviour based on its stem cell content.

The TOP 20 genes have been defined based on published expression profiles of breast stem cells, and further selected based on their levels of expression and likelihood of reduction into practice for patient stratification in breast cancer.

The inventor of the TOP 20 model, Professor Pier Paolo Di Fiore, a physician and specialist in molecular oncology and cell biology, is a consultant to Tiziana and a member of Tiziana's Scientific Advisory Board.

Under the terms of the licensing agreement, Tiziana will pay the Licensor €600,000 over 4 years to fund research to create or enhance technologies to assist in the development and commercialization of products and services derived from the TOP 20 genes.

In return for an exclusive license to patents on the TOP20 genes, Tiziana will pay the Licensor inter alia a royalty rate of 1.5% based on commercial sales of any products developed under the license agreement.

Gabriele Cerrone, Executive Chairman of Tiziana, said: "We are very excited to be developing a diagnostic test with IEO, one of Europe's leading breast cancer institutes. This agreement gives us access to cutting edge stem cell technology as the TOP 20 model is synergistic with our existing therapeutic focus and enables us to enhance our franchise in breast cancer treatment.

"Stem cells are the "engine" of cancer and, therefore, laboratory tests based on stem cells are more likely to be helpful in patients' management both from the diagnostic and therapeutic viewpoint. Stratification of patients according to their clinical prognosis is an important goal in cancer research as it allows oncologists to better personalize patient treatment."

Professor Pier Paolo Di Fiore said: "I believe that Tiziana's elite and world-renowned oncology researchers provide the perfect platform to commercialize the TOP 20 model. I look forward to working closely with Dr Napoleone Ferrara, Dr Riccardo Dalla-Favera and the rest of the Tiziana team to offer this new diagnostic test for breast cancer patients."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!